Levetiracetam: Relative Bioavailability and Bioequivalence of a 10% Oral Solution (750 mg) and 750-mg Tablets

Journal of Clinical Pharmacology

Volumn 43, Issue 12, 2003, Pages 1370-1376

  Coupez, René ^a   Straetemans, Roel ^a   Sehgal, Geeta ^a   Stockis, Armel ^a   Lu, Zhihong ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Antiepileptic drugs; Bioavailability; Bioequivalence; Epilepsy; Levetiracetam; Pharmacokinetics

Indexed keywords

ETIRACETAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CALCULATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TABLET FORMULATION; VERTIGO;

ADMINISTRATION, ORAL; ADULT; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PIRACETAM; SOLUTIONS; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0242552652     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003258173     Document Type: Article

References (26)

1. Ben-Menachem E, Falter U, for the European Levetiracetam Study Group: Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41:1276-1283.
2. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I, and the United States Levetiracetam Study Group: Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
3. Shorvon SD, Löwenthal A, Janz D, Bielen E, Loiseau P, for the European Levetiracetam Study Group: Multicenter, double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41:1179-1186.
4. Krakow K, Walker M, Otoul C, Sander JWAS: Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001;56:1772-1774.
5. Ben-Menachem E, Edrich P, Van Vleymen B, Sander JWAS, Schmidt B: Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 2003;53:57-64.
6. Boon P, Chauvel P, Pohlmann-Eden B, Otoul C, Wroe S: Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002;48:77-89.
7. Patsalos PN: Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:77-85.
8. Browne TR, Szabo GK, Leppik IE, Josephs E, Paz J, Baltes E, et al: Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol 2000;40:590-595.
9. Coupez R, Nicolas J-M, Browne TR: Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic inter-action with valproic acid. Epilepsia 2003;44:171-178.
10. Ragueneau-Majlessi I, Levy RH, Meyerhoff C: Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res 2001;47:55-63.
11. Levy RH, Ragueneau-Majlessi I, Baltes E: Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res 2001;46:93-99.
12. Ragueneau-Majlessi I, Levy RH, Janik F: Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 2002;43:697-702.
13. Pellock JM, Glauser TA, Bebin EM, Fountain NB, Ritter FJ, Coupez RM, et al: Pharmacokinetic study of levetiracetam in children. Epilepsia 2001;42:1574-1579.
14. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, et al: Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 2000;17:1551-1557.
15. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine: Bioanalytical Method Validation. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, 2001. Available: www.fda.gov/cder/guidance/index.htm
16. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
17. Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2000. Available: www.fda.gov/cder/guidance/index.htm
18. Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2001. Available: www.fda.gov/cder/ guidance/index.htm
19. Steinijans VW, Hauschke D: Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990; 28:105-110.
20. Diletti E, Hauschke D, Steinijans VW: Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1991;29:1-8.
21. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E: Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002;51:31-71.
22. Walker MC, Patsalos PN: Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 1995;67:351-384.
23. Perucca E, Bialer M: The clinical pharmacokinetics of the newer antiepileptic drugs: focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996;31:29-46.
24. Perucca E: The clinical pharmacology of the new antiepileptic drugs. Pharmacol Res 1993;28:89-106.
25. Natsch S, Hekster YA, Keyser A, Deckers CLP, Meinardi H, Renier WO: Newer anticonvulsant drugs: role of pharmacology, drug inter-actions and adverse reactions in drug choice. Drug Saf 1997;17:228-240.
26. Wallace SJ: Newer antiepileptic drugs: advantages and disadvantages. Brain Dev 2001;23:277-283.